血小板生成素受体激动剂治疗难治性特发性血小板减少性紫癜的研究进展

Progress of therapy in thrombopoietin receptor agonists used for refractory idiopathic thrombocytopenic purpura

特发性血小板减少性紫癜(ITP)是一组免疫介导的血小板过度破坏所致的出血性疾病,以广泛皮肤黏膜及内脏出血、血小板减少、骨髓巨核细胞发育成熟障碍和血小板生存时间缩短等为特征。目前脾切除仍是二线治疗的首选,但难治性ITP的治疗目前仍十分棘手,近年来,针对巨核细胞分化成熟障碍而采用促血小板生成剂和血小板生成受体激动剂等逐渐应用于治疗难治性ITP。本文综述血小板生成素受体激动剂治疗难治性ITP的研究进展。

Idiopathic thrombocytopenic purpura （ITP） is an acquired disease characterized by a low platelet count, presence of anti-platelet antibody in the plasma, and increased or normal megakaryocytes with abnormal maturation. Splenectomy remains the most effective and durable treatment, but refractory ITP is still intractable. Recently developed agents that increase platelet production by stimulating megakaryocytes such as thrombopoietin （TPO） and thrombopoietin- receptor agonists offer an alternative treatment strategy. This review summarizes the progress of thrombopoietin-receptor agonist therapy for ITP.